



# ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSCO CERTIFIED CO.  
Manufacturer of Condoms

March 13, 2026

To,  
Listing Compliance Department  
**National Stock Exchange of India Limited**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (East), Mumbai-400051

**Sub: Resubmission of Financial Results for the Half Year Ended September 30, 2025 along with Clarification letter**

**SYMBOL: ANONDITA**  
**ISIN: INE0VTV01012**

Dear Sir/Madam,

With reference to the communication received from National Stock Exchange of India (NSE) dated 20<sup>th</sup> February 2026, we hereby resubmit the Financial Results of the Company for the half year ended September 30, 2025 along with a clarification letter as directed.

Kindly take the above information on record.

Thanking You.  
Yours faithfully,

**For and on behalf of**  
**ANONDITA MEDICARE LIMITED**

\_\_\_\_\_  
**Bhawna Bisht**  
**Company Secretary and Compliance officer**  
**Membership No. A70843**

**Enclosure (as above):**

1. Clarification Letter on resubmission of Financial Results for the half year ended September 30, 2025.
2. Unaudited Standalone and Revised Consolidated Financial Results for the half year ended September 30, 2025.



Regd. Off.: Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070  
Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA  
Tel.: 0120-4520300/1/2/3 till 99 (100 Lines) Fax : 0120-4520314  
E- mail : [info@anonditamedicare.com](mailto:info@anonditamedicare.com) | [accounts@anonditahealthcare.com](mailto:accounts@anonditahealthcare.com)  
Website: [www.anonditamedicare.com](http://www.anonditamedicare.com)

**ANONDITA MEDICARE LIMITED**AN ISO 9001:2015 ISO 13485:2016 & CDSCO CERTIFIED CO.  
Manufacturer of Condoms

March 13, 2026

To,  
Listing Compliance Department  
**National Stock Exchange of India Limited**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (East), Mumbai-400051

**Subject: Clarification on Resubmission of Financial Results for the Half Year ended September 30, 2025**

**SYMBOL: ANONDITA,**  
**ISIN: INE0VTV01012**

Dear Sir/Madam,

With reference to the observations received from the Exchange regarding the financial results submitted for the half year ended September 30, 2025, we would like to clarify that the figures relating to Short-Term Borrowings and Short-Term Loans & Advances in the Consolidated Financial Results have been revised to incorporate certain consolidation adjustments relating to the borrowings and loan & advances with the subsidiary, which were inadvertently not reflected in the earlier submission.

Accordingly, the figures have now been revised in the updated financial results as under:

S.No	Particulars	Consolidated half year ended as at 30/09/2025 (Before Adjustment)		Adjustment with subsidiary account half year ended as at 30/09/2025		Consolidated figure half year ended as at 30/09/2025 (After Adjustment)	
		Amount	Amount	Amount	Amount	Amount	Amount
<b>1</b>	<b>Total Liabilities</b>	<b>17630.52</b>		<b>1579.09</b>		<b>16051.43</b>	
1.(a)	Short-Term Borrowings		3352.38		1579.09		1773.29
<b>2</b>	<b>Total Assets</b>	<b>17630.52</b>		<b>1579.09</b>		<b>16051.43</b>	
2.(a)	Short-Term Loans & Advances		3706.27		1579.09		2127.18





# ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSCO CERTIFIED CO.  
Manufacturer of Condoms

S.No	Particulars	Consolidated figures fo half year ended as at 30/09/2024 (Before Adjustment)		Adjustment with subsidiary account half year ended as at 30/09/2024		Consolidated figure for half year ended as at 30/09/2024 (After Adjustment)	
		Amount	Amount	Amount	Amount	Amount	Amount
1	<b>Total Liabilities</b>	<b>7017.96</b>		<b>571.00</b>		<b>6446.96</b>	
1.(a)	Short-Term Borrowings		2046.52		571.00		1475.52
2	<b>Total Assets</b>	<b>7017.96</b>		<b>571.00</b>		<b>6446.96</b>	
2.(a)	Short-Term Loans & Advances		2122.85		571.00		1551.85

The revised XBRL Integrated filing has been re-submitted on the NEAPS portal, as advised.

*We would like to further clarify that the revision does not impact the Profit & Loss Account or the reported Total Income or net profit/loss for the half year ended September 30, 2025.*

Kindly take the revised submission on record.

Thanking You.  
Yours faithfully,

**For and on behalf of**  
**ANONDITA MEDICARE LIMITED**

\_\_\_\_\_  
**Bhawna Bisht**  
**Company Secretary and Compliance officer**  
**Membership No. A70843**



Regd. Off.: Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070  
Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA  
Tel.: 0120-4520300/1/2/3 till 99 (100 Lines) Fax : 0120-4520314  
E- mail : [info@anonditamedicare.com](mailto:info@anonditamedicare.com) | [accounts@anonditahealthcare.com](mailto:accounts@anonditahealthcare.com)  
Website: [www.anonditamedicare.com](http://www.anonditamedicare.com)

# Jain Chopra & Company

Chartered Accountants

8, Chandra House, First Floor, Dr. Lane, Gole Market, New Delhi - 110001

1960, First Floor, Outram Line, Delhi - 110009

Ph. : 011-23340155, 23342776 Mob:9810247478

E-mail : jainchopra.company@gmail.com

**Independent Auditor's Limited Review Report on unaudited financial results of Anondita Medicare Limited for the half year ended September 30, 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation 2015**

To,  
The Board of Directors of Anondita Medicare Limited

We have reviewed the accompanying statement of unaudited financial results of Anondita Medicare Limited for the half year ended September 30, 2025. This Financial statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 - "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Jain Chopra & Company  
Chartered Accountants  
FR No. 002198N

*Rajesh Kumar*  
Rajesh Kumar  
Partner  
M.No. 501860  
UDIN: 25501860BMLYKU9992  
Date: 13-11-2025  
Place: New Delhi



**ANONDITA MEDICARE LIMITED**  
(Formerly known as Anondita Healthcare)

Regd Address: Flat No.704, Narmada Block, N-6, Sector-D, Pocket-6, Vasant Kunj South West Delhi-110070  
CIN:L22193DL2024PLC428183

STANDALONE BALANCE SHEET AS AT 30 SEPTEMBER, 2025

(Amount in Lakhs)

Particulars	For Half Year ended As at 30 September, 2025 (Unaudited)	For Half Year ended As at March 31, 2025 (Unaudited)	For Half Year ended As at 30 September, 2024 (Unaudited)	Year Ended As at March 31, 2025 (Audited)
<b>I. EQUITY AND LIABILITIES</b>				
<b>1. Shareholders' funds</b>				
(a) Share Capital	1,808.66	1,329.36	886.24	1,329.36
(b) Reserves and surplus	7,963.81	1,430.41	1,077.21	1,430.41
(c) Money received against share warrants				
<b>2. Share application money pending allotment</b>				
<b>3. Non - current liabilities</b>				
(a) Long-term borrowings	1,307.40	1,190.76	1,320.65	1,190.76
(b) Deferred Tax Liability (net)	24.06	8.56	17.30	8.56
(c) Other Long term liabilities				
(d) Long Term Provision	15.13	9.83	7.51	9.83
<b>4. Current liabilities</b>				
(a) Short-term borrowings	1,738.22	1,548.34	1,475.52	1,548.34
(b) Trade payables				
A) Total outstanding dues of micro enterprises and small enterprises	153.00	99.37	168.87	99.37
B) Total outstanding dues of creditors other than micro enterprises and small enterprises	323.64	253.21	118.65	253.21
(c) Other current liabilities	265.97	134.74	123.45	134.74
(d) Short-term Provisions	732.51	361.76	79.30	361.76
<b>Total</b>	<b>14,332.39</b>	<b>6,366.35</b>	<b>5,274.70</b>	<b>6,366.35</b>
<b>ASSETS</b>				
<b>1) Non Current Assets</b>				
<b>(a) Property, Plant and Equipment and Intangible assets</b>				
(i) Property, Plant and Equipment	1,275.48	1,235.16	1,246.15	1,235.16
(ii) Intangible assets				
(iii) Capital Work In Progress	1,522.08	649.61	50.36	649.61
(iv) Intangible assets under development				
(b) Non-current Investments	351.58	351.58	351.58	351.58
(c) Deferred tax assets (net)				
(d) Long-term loans and advances	37.66	37.66	37.66	37.66
(e) Other non - current assets	0.20	0.24	0.30	0.24
<b>2) Current Assets</b>				
(a) Current investments				
(b) Inventories	1,103.36	896.28	728.35	896.28
(c) Trade receivables	3,321.36	1,660.42	1,405.72	1,660.42
(d) Cash and Bank balance	3,628.28	25.56	41.81	25.56
(e) Short-term loans and advances	2,360.94	1,173.35	1,183.80	1,173.35
(f) Other current assets	731.45	336.48	228.97	336.48
<b>Total</b>	<b>14,332.39</b>	<b>6,366.35</b>	<b>5,274.70</b>	<b>6,366.35</b>

For & On behalf of the Board  
Anondita Medicare Limited



Reshant Ghosh  
(Wholetime Director)

DIN:08632812  
Add:D-001, Sector-80  
Noida U.P-201301

Place:Noida  
Dated:13.11.2025

## ANONDIRA MEDICARE LIMITED

Regd Address: Flat No.704, Narmada Block, N-6, Sector-D, Pocket-6, Vasant Kunj South West Delhi-110070  
CIN:L22193DL2024PLC428183

### STANDALONE STATEMENT OF PROFIT & LOSS AS AT 30 SEPTEMBER, 2025

(Amount in Lakhs)

PARTICULARS	For Half Year ended As at 30 September, 2025 (Unaudited)	For Half Year ended As at 31 March, 2025 (Unaudited)	For Half Year ended As at 30 September, 2024 (Unaudited)	Year Ended As at March 31, 2025 (Audited)
I. Revenue from operations	4,765.06	3,554.47	2,497.06	6,051.52
II. Other Income	75.56	7.73	28.65	36.38
<b>III. Total Income (I +II)</b>	<b>4,840.62</b>	<b>3,562.20</b>	<b>2,525.70</b>	<b>6,087.90</b>
IV. Expenses:				
Cost of Materials Consumed	2,353.22	1,894.00	1,482.69	3,376.69
Purchase of Stock-in-Trade				
Change in inventories of finished goods, Work in progress and Stock in Trade	(186.94)	(206.53)	3.56	(202.97)
Employee benefit expense	271.06	259.98	223.68	483.66
Financial costs	181.32	144.36	145.09	289.46
Depreciation and amortization expense	40.03	38.63	36.02	74.65
Other expenses	649.21	349.54	256.15	605.68
<b>Total Expenses</b>	<b>3,307.91</b>	<b>2,479.98</b>	<b>2,147.20</b>	<b>4,627.18</b>
V. Profit before exceptional and extraordinary items and tax (III - IV)	1,532.71	1,082.22	378.51	1,460.73
VI. Exceptional Items				
VII. Profit before extraordinary items and tax (V - VI)	1,532.71	1,082.22	378.51	1,460.73
VIII. Extraordinary Items				
IX. Profit before tax (VII - VIII)	1,532.71	1,082.22	378.51	1,460.73
X. Tax expense:				
(1) Current tax	370.65	282.41	78.74	361.15
(2) Deferred tax Liability / (Assets)	15.49	(8.73)	17.30	8.56
XI. Profit(Loss) for the year from continuing operations (IX - X)	1,146.57	808.54	282.47	1,091.01
XII. Profit/(Loss) from discontinuing operations				
XIII. Tax expense of discounting operations				
XIV. Profit/(Loss) from Discontinuing operations (after tax) (XII - XIII)				
XV. Profit/(Loss) for the year (XI + XIV)	1,146.57	808.54	282.47	1,091.01
XVI. Earning per equity share:				
(1) Basic	8.14	7.18	3.05	9.70
(2) Diluted	8.14	7.18	3.05	9.70

For & on behalf of Board of Directors  
Anondita Medicare Limited



Reshant Ghosh  
(Wholetime Director)

DIN:08632812

Add:D-001, Sector-80  
Noida U.P.-201301

Place:Noida  
Dated:13.11.2025

## ANONITA MEDICARE LIMITED

Regd Address: Flat No.704, Narmada Block, N-6, Sector-D, Pocket-6, Vasant Kunj South West Delhi-110070  
CIN:L22193DL2024PLC428183

### STANDALONE STATEMENT OF CASH FLOW AS AT 30 SEPTEMBER, 2025

Particulars	(Amount in Lakhs)			
	For Half Year ended As at 30 September, 2025 (Unaudited)	For Half Year ended As at 31 March, 2025 (Unaudited)	For Half Year ended As at 30 September, 2024 (Unaudited)	Year Ended As at March 31, 2025 (Audited)
Profit before tax				
Adjustments for:	1,532.71	1,082.22	378.51	1,460.73
Depreciation & amortization expense				
Interest expense on borrowings	40.03	38.63	36.02	74.65
Interest income	181.32	144.36	145.09	289.46
Provision for Gratuity	(7.22)	(3.03)	(0.93)	(3.95)
Preliminary exp written off				
Operating Profit before working capital changes	1,746.84	1,262.21	558.70	1,820.96
Changes in operating assets and liabilities:				
Increase/(decrease) in trade payables	124.05	65.06	287.52	(148.09)
Increase/(decrease) in other current liabilities	131.22	11.21	122.75	43.70
Increase/(decrease) in Short Term Borrowings	189.88	72.82	1,475.52	1,101.92
Increase/(decrease) in Short Term Provisions	0.10	0.05	0.56	0.61
Increase/(decrease) in Long Term Provisions	5.31	2.32	7.51	4.12
Decrease/(increase) in trade receivables	(1,660.94)	(254.70)	(1,405.72)	(412.15)
Decrease/(increase) in Inventory	(207.08)	(167.93)	(728.35)	(186.13)
Decrease/(increase) in Short Term loans and advances	(1,187.59)	10.44	(1,183.80)	(1,071.43)
Decrease/(increase) in Long Term loans and advances			(37.66)	340.89
Decrease/(increase) in other current assets	(85.85)	(78.97)	(221.97)	(175.18)
Decrease/(increase) in other Non-current assets	0.04		0.02	
Cash generated from operations	(2,690.85)	(339.70)	(1,683.62)	(501.74)
Income taxes refunded/ (paid)	(944.01)	923	(1,124.92)	1,319.22
Net cash flow from operations (A)	(309.13)	(28.62)	(41.70)	(41.70)
Net cash flow from operations (A)	(1,253.13)	893.89	(1,124.92)	1,277.52
Cash flow from investing activities				
Purchase of /Advances for property, plant & equipment and Intangible assets				
Sale of property, plant & equipment	(952.82)	(626.89)	(1,332.53)	(671.59)
Investment in Noncurrent Investment				
(Increase)/Decrease in other advance			(351.58)	(20.18)
Interest received	7.22	3.03	0.93	3.95
Purchase of Fixed Assets in acquisition of Business				(1,287.83)
Purchase of Investments in acquisition of Business				(331.40)
Purchase of Advances in acquisition of Business				(101.92)
Purchase of Trade Receivable in acquisition of Business				(1,248.27)
Purchase of Inventories in acquisition of Business				(710.15)
Purchase of Other Assets in acquisition of Business				(112.60)
Purchase of Trade advances in acquisition of Business				(378.55)
Purchase of Trade Payable in acquisition of Business				500.67
Purchase of Other Liabilities in acquisition of Business				90.34
Purchase of Borrowings in acquisition of Business				2,401.29
Purchase of Deferred Tax in acquisition of Business				5.70
Purchase of Provisions in acquisition of Business				34.76
Purchase of Cash & Cash Equivalents in acquisition of Business				(34.76)
Less: Cash & Cash Equivalents				
Net cash used in investing activities (B)	(945.60)	(623.86)	(1,683.18)	(1,860.53)
Cash flow from financing activities				
Proceeds from issue of capital/equity shares				
Further issue of capital			876.44	734.04
Proceeds from share premium	479.30			142.20
Share issue expenses	6,470.55		910.09	910.09
Proceeds/(Repayment) of Long Term Borrowings	(1,083.72)	(12.03)	(115.17)	(127.19)
Borrowing received against business acquisition	116.64	(129.89)	1,320.65	(1,210.52)
(Repayment)Receipt of borrowing				
Interest paid	(181.32)	(144.36)	(145.09)	446.42
Net cash flow from/ (used in) financing activities (C)	5,801.45	(286.28)	2,846.92	(289.46)
Net increase/(decrease) in cash and cash equivalents (A+B+C)	3,602.71	(16.25)	38.81	605.58
Cash and cash equivalents at the beginning of the year	25.56	41.81	3.00	22.56
Cash and cash equivalents at the closing of the year	3,628.28	25.56	41.81	3.00
Cash in hand				25.56
Balances with banks:	11.44	14.29	17.20	14.29
- On current accounts	3,616.84	11.28	24.61	
<b>Total</b>	<b>3,628.28</b>	<b>25.56</b>	<b>41.81</b>	<b>25.56</b>

For & On behalf of the board  
Anonita Medicare Limited

Reshant Ghosh  
(Whole time Director)  
DIN:08632812  
Add:D-001, Sector-80  
Noida U.P-201301

# Jain Chopra & Company

Chartered Accountants

8, Chandra House, First Floor, Dr. Lane, Gole Market, New Delhi - 110001

1960, First Floor, Outram Line, Delhi - 110009

Ph. : 011-42171194 Mob : 9810247478

E-mail : jainchopra.company@gmail.com

Revised Independent Auditor's Limited Review Report on unaudited consolidated financial results of Anondita Medicare Limited for the half year ended September 30, 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation 2015

To,  
The Board of Directors of Anondita Medicare Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results of **Anondita Medicare Limited ("the Holding Company")** its subsidiary and associate (the Holding Company its subsidiary and associate together referred to as "**the Group**") and its share of the net profit/(loss) after tax for the half year ended September 30, 2025 of its associate ("**the Statement**"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting" (AS 25), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India.

A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the following entities:

M/s Anondita Healthcare and Rubber Products India Limited	Subsidiary
M/s Anondita Healthcare (Partnership Firm)	Associate



# Jain Chopra & Company

Chartered Accountants

8, Chandra House, First Floor, Dr. Lane, Gole Market, New Delhi - 110001


1960, First Floor, Outram Line, Delhi - 110009

Ph. : 011-42171194 Mob : 9810247478

E-mail : jainchopra.company@gmail.com

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditor referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in AS 25 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The Statement includes the Group's share of net profit after tax of Rs. 147.98 lacs and Rs. 303.68 lacs for the half year ended September 30, 2025 and half year ended September 30, 2024 respectively as considered in the unaudited consolidated financial results, in respect of an subsidiary referred in para 4 above, whose interim financial statement has not been reviewed by us. This interim financial statement has been reviewed by other auditor whose report has been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of the subsidiary, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.
7. Our conclusion is not modified in respect of this matter.

For Jain Chopra & Company  
Chartered Accountants  
FR No. 002198N

  
Rajesh Kumar  
Partner  
M.No. 501860  
UDIN: 26501860ZPGQSA5159



Date: 10-02-2026  
Place: New Delhi

**ANONDITA MEDICARE LIMITED**  
(Formerly known as Anondita Healthcare)

Regd Address: Flat No.704, Narmada Block, N-6, Sector-D, Pocket-6, Vasant Kunj South West Delhi-110070  
CIN:U22193DL2024PLC428183

Consolidated Financial Statement as at September 30, 2025

	(Amount in Lakhs)			
Particulars	For Half Year ended As at 30 September, 2025 (Unaudited)	For Half Year ended As at 31 March, 2025 (Unaudited)	For Half Year ended As at 30 September, 2024 (Unaudited)	Year Ended As at March 31, 2025 (Audited)
<b>I. EQUITY AND LIABILITIES</b>				
<b>1. Shareholders' funds</b>				
(a) Share Capital	1,808.79	1,329.36	886.36	1,329.36
(b) Reserves and surplus	9,053.54	2,380.36	1,785.56	2,380.36
(c) Minority Interest	134.39	118.16	87.01	118.16
(d) Money received against share warrants		-		
<b>2. Share application money pending allotment</b>		-		
<b>3. Non - current liabilities</b>				
(a) Long-term borrowings	1,307.40	1,190.76	1,320.65	1,190.76
(b) Deferred Tax Liability (net)	24.06	8.56	17.30	8.56
(c) Other Long term liabilities		-		
(d) Long Term Provision	15.13	9.83	7.51	9.83
<b>4. Current liabilities</b>				
(a) Short-term borrowings		-		
(b) Trade payables	1,773.29	1,548.34	1,475.52	1,548.34
A) Total outstanding dues of micro enterprises and small enterprises	153.00	123.88	249.54	123.88
B) Total outstanding dues of creditors other than micro enterprises and small enterprises	484.05	257.65	73.11	257.65
(c) Other current liabilities	323.39	210.06	362.97	210.06
(d) Short-term Provisions	974.38	553.87	181.44	553.87
<b>Total</b>	<b>16,051.43</b>	<b>7,730.83</b>	<b>6,446.96</b>	<b>7,730.83</b>
<b>ASSETS</b>				
<b>1) Non Current Assets</b>				
<b>(a) Property, Plant and Equipment and Intangible assets</b>				
(i) Property, Plant and Equipment	1,277.25	1,237.04	1,246.61	1,237.04
(ii) Intangible assets				
(a) Goodwill	19.18	19.18	19.18	-
(iii) Capital Work In Progress	1,522.08	649.61	50.36	19.18
(iv) Intangible assets under development				649.61
(b) Non-current Investments	331.40	331.40	331.40	-
(c) Deferred tax assets (net)	0.22	0.22	0.16	0.22
(d) Long-term loans and advances	37.66	37.66	37.66	37.66
(e) Other non - current assets	0.24	0.28	0.38	0.28
<b>2) Current Assets</b>				
(a) Current investments				
(b) Inventories	1,450.10	1,349.86	951.05	1,349.86
(c) Trade receivables	4,809.67	2,675.33	1,907.55	2,675.33
(d) Cash and Bank balance	3,650.96	32.94	79.67	32.94
(e) Short-term loans and advances	2,127.18	973.96	1,551.85	973.96
(f) Other current assets	825.49	423.35	271.10	423.35
<b>Total</b>	<b>16,051.43</b>	<b>7,730.83</b>	<b>6,446.96</b>	<b>7,730.83</b>

For & On behalf of the Board  
Anondita Medicare Limited

Reshant Ghosh  
(Whistleblower Director)  
DIN:08632812

Place : NOIDA  
DATE 10<sup>th</sup> Feb 2026

Address :- D-001, Sector 80, Noida,  
Gautam Buddha Nagar, Noida,  
Uttar Pradesh - 201301

**ANONDIRA MEDICARE LIMITED**

Regd Address: Flat No.704, Narmada Block, N-6, Sector-D, Pocket-6, Vasant Kunj South West Delhi-110070  
CIN:U22193DL2024PLC428183

**Consolidated Statement of Profit & Loss Account as at September 30, 2025**

(Amount in Lakhs)

PARTICULARS	For Half Year ended As at 30 September, 2025 (Unaudited)	For Half Year ended As at 31 March, 2025 (Unaudited)	For Half Year ended As at 30 September, 2024 (Unaudited)	Year Ended As at March 31, 2025 (Audited)
I. Revenue from operations	5,409.70	4,558.57	3,140.50	7,699.07
II. Other Income	40.77	3.62	10.26	13.88
<b>III. Total Income (I + II)</b>	<b>5,450.48</b>	<b>4,562.18</b>	<b>3,150.76</b>	<b>7,712.95</b>
IV. Expenses:				
Cost of Materials Consumed	2,353.22	1,894.00	1,482.69	3,376.69
Purchase of Stock-in-Trade	164.93	743.80	1.06	744.86
Change in inventories of finished goods, Work in progress and Stock in Trade	(79.18)	(420.57)	127.36	(293.20)
Employee benefit expense	348.10	424.94	261.85	686.80
Financial costs	182.35	145.78	145.32	291.09
Depreciation and amortization expense	40.87	39.52	36.27	75.79
Other expenses	702.49	323.66	295.04	618.70
<b>Total Expenses</b>	<b>3,712.78</b>	<b>3,151.13</b>	<b>2,350</b>	<b>5,500.72</b>
V. Profit before exceptional and extraordinary items and tax (III - IV)	<b>1,737.70</b>	<b>1,411.05</b>	<b>801.17</b>	<b>2,212.22</b>
VI. Exceptional Items				
VII. Profit before extraordinary items and tax (V - VI)	1,737.70	1,411.05	801.17	2,212.22
VIII. Extraordinary Items				
IX. Profit before tax (VII - VIII)	1,737.70	1,411.05	801.17	2,212.22
X. Tax expense:				
(1) Current tax	420.42	372.38	180.88	553.25
(2) Deferred tax Liability / (Assets)	15.49	(8.80)	17.30	8.50
XI. Profit(Loss) for the year from continuing operations (IX - X)	1,301.79	1,047.47	603.00	1,650.47
XII. Profit/(Loss) from discontinuing operations				
XIII. Tax expense of discounting operations				
XIV. Profit/(Loss) from Discontinuing operations (after tax) (XII - XIII)				
XV. Profit/(Loss) for the year (XI + XIV)	1,301.79	1,047.47	603.00	1,650.47
<b>Profit for the Year attributable to</b>				
a. Owners of the Company	1,285.56	1,018.53	569.69	1,588.21
b. Minority Interest	16.23	28.95	33.31	62.26
XVI. Earning per equity share:				
(1) Basic	9.12	9.31	6.16	14.11
(2) Diluted	9.12	9.31	6.16	14.11

For & On behalf of the Board  
Anondita Medicare Limited



Rashant Ghosh  
(Wholesale Director)  
DIN:08632812

PLACE : Noida  
DATE : 10<sup>th</sup> FEB 2026

Address : D-001, Sector 80,  
Noida, Gautam Buddha Nagar,  
Noida, Uttar Pradesh -  
201301

**ANONITA MEDICARE LIMITED**

Regd Address: Flat No.704, Narmada Block, N-6, Sector-D, Pocket-6, Vasant Kunj South West Delhi-110070  
CIN:U22193DL2024PLC428183

Consolidated Statement of Cash Flow for the year ended Sep 30, 2025

Particulars	(Amount in Lakhs)			
	For Half Year ended As at 30 September, 2025 (Unaudited)	For Half Year ended As at 31 March, 2025 (Unaudited)	For Half Year ended As at 30 September, 2024 (Unaudited)	Year Ended As at March 31, 2025 (Audited)
<b>Profit before tax</b>				
<b>Adjustments for:</b>	1,737.70	1,411.05	801.17	2,212.22
Depreciation & amortization expense	40.87	39.52	36.27	75.79
Interest expense on borrowings	247.33	156.92	163.82	320.74
Interest income	(7.22)	(3.03)	(0.93)	(3.95)
Loss on sale of Car			0.86	0.86
Provision for Gratuity			-	-
Preliminary exp written off		0.02	-	0.12
<b>Operating Profit before working capital changes</b>	<b>2,018.68</b>	<b>1,604</b>	<b>1,001.19</b>	<b>2,605.78</b>
<b>Changes in operating assets and liabilities:</b>				
Increase/(decrease) in trade payables	255.52	13.33	(43.02)	(484.82)
Increase/(decrease) in other current liabilities	113.33	(152.98)	126.15	(117.09)
Increase/(decrease) in Short Term Borrowing	(473.95)	200.72	1,205.61	-
Increase/(decrease) in Short Term Provisions	0.10	0.05	(1.84)	0.61
Increase/(decrease) in Long Term Provisions	5.31	2.32	7.51	4.12
Decrease/(increase) in trade receivables	(2,134.34)	(722.24)	(1,594.31)	(1,113.82)
Decrease/(increase) in Inventory	(99.33)	(381.98)	(604.54)	(276.37)
Decrease/(increase) in Short Term loans and advances	(454.33)	449.99	(1,437.34)	(1,456.43)
Decrease/(increase) in Long Term loans and advances	-	-	(37.66)	340.89
Decrease/(increase) in other current assets	(93.01)	(112.16)	(211.21)	(209.18)
Decrease/(increase) in other Non-current assets	0.04		0.02	
<b>Cash generated from operations</b>	<b>(2,880.65)</b>	<b>(702.95)</b>	<b>(2,590.64)</b>	<b>(3,312.09)</b>
Income taxes refunded/ (paid)	(861.97)	901.54	(1,589.45)	(706.31)
<b>Net cash flow from operations (A)</b>	<b>(1,171.09)</b>	<b>861.40</b>	<b>(1,589.45)</b>	<b>(44.10)</b>
<b>Cash flow from investing activities</b>				
Purchase of /Advances for property, plant & equipment and Intangible assets	(953.55)	(629.19)	(1,332.53)	(673.90)
Sale of property, plant & equipment			4.23	4.23
Investment in Noncurrent Investment			(351.58)	(20.18)
(Increase)/Decrease in other advance			-	-
Interest received	7.22	3.03	0.93	3.95
Purchase of Fixed Assets in acquisition of Business				(1,287.83)
Purchase of Investments in acquisition of Business				(331.40)
Purchase of Advances in acquisition of Business				(101.92)
Purchase of Trade Receivable in acquisition of Business				(1,248.27)
Purchase of Inventories in acquisition of Business				(710.15)
Purchase of Other Assets in acquisition of Business				(112.60)
Purchase of Trade advances in acquisition of Business				(378.55)
Purchase of Trade Payable in acquisition of Business				500.67
Purchase of Other Liabilities in acquisition of Business				90.34
Purchase of Borrowings in acquisition of Business				2,401.29
Purchase of Deferred Tax in acquisition of Business				-
Purchase of Provisions in acquisition of Business				5.70
Purchase of Cash & Cash Equivalents in acquisition of Business				(26.72)
Less: Cash & Cash Equivalents				26.72
<b>Net cash used in investing activities (B)</b>	<b>(946.33)</b>	<b>(626.17)</b>	<b>(1,678.95)</b>	<b>(1,858.60)</b>
<b>Cash flow from financing activities</b>				
Proceeds from issue of capital/equity shares			1,349.06	734.16
Further Issue of Capital	479.30	0.01	-	142.20
Proceeds from Share Premium	6,470.55	25.19	910.09	1,464.36
Share Issue Expense	(1,083.72)	(20.36)	(115.17)	(192.11)
Proceeds/(Repayment) of Long Term Borrowings	116.64	(129.89)	1,320.65	(1,210.52)
Increase/(decrease) in Short Term Borrowings			-	1,530.91
(Repayment)/Receipt of borrowing			-	446.42
Interest paid	(247.33)	(156.92)	(163.82)	(320.74)
<b>Net cash flow from/ (used in) financing activities (C)</b>	<b>5,735.45</b>	<b>(281.97)</b>	<b>3,300.81</b>	<b>2,594.68</b>
<b>Net increase/(decrease) in cash and cash equivalents (A+B+C)</b>	<b>3,618.02</b>	<b>(46.74)</b>	<b>32.41</b>	<b>(14.33)</b>
Cash and cash equivalents at the beginning of the year	32.94	79.67	47.27	47.27
<b>Cash and cash equivalents at the closing of the year</b>	<b>3,650.96</b>	<b>32.94</b>	<b>79.67</b>	<b>32.94</b>
Cash in hand	15.18	18.14	21.64	18.14
Balances with banks:				
- On current accounts	3,635.78	14.80	58.03	14.80
<b>Total</b>	<b>3,650.96</b>	<b>32.94</b>	<b>79.67</b>	<b>32.94</b>

PLACE: NOIDA  
DATE: 10<sup>th</sup> Feb - 2026

  
 For & On behalf of the Board  
 Anonita Medicare Limited  
 Resant Ghosh  
 (Wholetime Director)  
 DIN:08632812

Add: D-001, Sector 80, Gautam Buddha Nagar,  
Noida. UP - 201301